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Background: Hypoxia inducible factor-1 alpha (HIF-1α), induced by tumor hypoxia, regulates tumor cell
metabolism and metastasis by up-regulation of c-Met, carbonic anhydrase 9 (CA9) and glucose transporter 1
(GLUT1). The prognostic significance of hypoxia and metabolic markers is not clearly defined in cervical cancer.
Here, we have examined the primary players in the hypoxia signaling pathway, by immunohistochemistry, but
confirming their interactions, as well as defining which proteins are associated with outcome.
Methods: The study subjects were comprised of cervical intraepithelial neoplasia (CIN, n = 209), carcinoma in situ
(CIS, n = 74), cervical cancer (n = 179), and matched nonadjacent normal tissues (n = 357). Immunohistochemistry
(IHC) was performed to identify HIF-1α, c-Met, CA9, and GLUT1. IHC scoring was performed using automated digital
image analysis and the association of hypoxic markers with prognostic outcome was evaluated.
Results: HIF-1α, c-Met, CA9 and GLUT1 expression were higher in cervical cancer than in CIN and normal cervix
(all P < 0.001). Among these markers, expression of HIF-1α and c-Met were significantly different in FIGO stage
(P < 0.001 and P = 0.019, respectively) and patients with lymph node metastasis (P < 0.001 and P = 0.010, respectively).
HIF-1α expression was correlated with c-Met expression in cervical cancer (P < 0.001). High expression of HIF-1α and
c-Met showed worse 5-year overall survival rate (P = 0.047 and P = 0.005, respectively) than low expression group, but
CA9 and GLUT1 did not show significant survival difference. After adjusting the prognostic covariates, c-Met was found
to be an independent risk factor (HR=3.27; 95% CI, 1.05-10.23, P = 0.041) for overall survival in cervical cancer.
Conclusions: We demonstrate that c-Met correlates with HIF-1α and is a poor prognostic factor in survival in cervical
cancer.
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Cervical cancer is the third most common cancer
in women worldwide and remains a significant cause
of morbidity and mortality in developing countries in-
cluding South America, sub-Saharan Africa, and the
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reproduction in any medium, provided the orachieved significant successes in reducing the burden of
cervical cancer through substantial health care invest-
ments for screening programs and diagnostic workup.
On the other hand, cervical cancer is the leading cancer
among women in many resource-constrained settings of
developing countries, where incidence and mortality rate
are about five- to six-times higher [1]. Overall the clinical
management of patients with premalignant and malignant
cervical disease is a significant burden on the health care
system. Although tremendous progress has been made in
the diagnosis and treatment of cervical cancer, there is still
a need for clinically robust biomarkers to further refine
the screening, triage and management of women.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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often associated with tumor glycolysis, angiogenesis, and
poor prognosis, as well as invasion and metastasis by acti-
vating relevant gene expression through hypoxia inducible
factor-1α (HIF-1α) [2-6]. In normoxic condition, HIF-1α is
degraded within minutes through the interaction of iron
and oxygen-dependent von Hippel-Lindau tumor suppres-
sor (VHL) [7]. However, in hypoxic condition or in the ab-
sence of VHL, HIF-1α is stabilized and binds to DNA on
the hypoxia response elements contained within the pro-
moter regions of various target genes [3,8]. HIF-1α synthe-
sis is increased by various growth factors, cytokines and
other signaling molecules responsible for stimulating phos-
phatidylinositol 3-kinase (PI3K) or mitogen-activated pro-
tein kinase (MAPK) pathways [8]. Increased HIF-1α
activates target genes involved in tumor cell growth, angio-
genesis, metabolism, apoptosis and metastasis [4,9]. In a
hypoxic cancer microenvironment, a metabolic shift occurs
from an oxidative to glycolytic metabolism. HIF-1α con-
verts pyruvate metabolism in mitochondria to cytoplasmic
alteration of pyruvate into lactic acid [10]. In cytoplasmic
glucose metabolism, high glucose consumption takes place
in tumor cells and glucose transporter type 1 (GLUT1) is
involved in delivering glucose into these tumor cells. Cyto-
plasmic glucose metabolism produces lactic acid that in-
duces acidosis, but carbonic anhydrase 9 (CA9) regulates
cell pH through Cl-/HCO3- exchanger uptake of HCO3-.
c-Met, known as hepatocyte growth factor receptor, is acti-
vated by HIF-1α and it is known for tumor invasion and
metastasis [5,6].
HIF-1α and its regulated markers including c-Met,
CA9 and GLUT1 were reported to be highly expressed
in various cancers and associated with poor prognosis
[3]. However, the relationship of these hypoxia markers
in the prognosis of cervical cancer is unclear [11,12].
Furthermore, hypoxia results in resistance against radi-
ation and chemotherapy which are treatment options in
cervical cancer, so prognostic significance of hypoxia
markers must be clarified. Immunohistochemistry (IHC)
utilizes antigen-antibody recognition in detecting spe-
cific antigens within tissues and it's widely used in surgi-
cal pathology. A variety of markers has been evaluated
for their role in the diagnosis, prognosis, and prediction
of treatment. However, interpretation of immunohisto-
chemical stains by traditional-microscope based review
introduces inter and intra observer variability and re-
mains a challengeable issue [13]. In this context, several
automated image analysis systems have been developed
and their use has shown promising advantages including
objectivity, speed, reproducibility, and accurate quantita-
tive assessment of immunohistochemical stains [14,15].
In the current study, the expression of HIF-1α and func-
tionally related proteins, including c-Met, CA9 and
GLUT1, were analyzed in cervical cancer patients bycombined IHC and automated digital image analysis.
Furthermore, we evaluated the association of these
markers with prognosis.
Materials and methods
Patient selection
One hundred seventy nine paraffin-embedded specimens
of cervical cancer, 74 carcinoma in situ (CIS), 209 cervical
intraepithelial neoplasia (CIN), and 357 matched normal
tissues obtained from Gangnam Severance Hospital,
Yonsei University College of Medicine in Seoul, Korea and
the Korea Gynecologic Cancer Bank through Bio & Med-
ical Technology Development Program of the Ministry of
Education, Science and Technology, Korea between 1996
and 2010 were included in the study. Medical records were
reviewed to collect patient data including age, cancer stage,
tumor differentiation, cell type, tumor size, lymphovascular
space invasion (LVSI) and lymph node (LN) metastasis.
The tumors were staged according to the FIGO stage and
histologically classified and graded according to WHO
grade. Patients with operable condition underwent radical
hysterectomy with pelvic and aortic lymph node dissec-
tion, and concurrent chemoradiation therapy was added
to the patient with risk factors such as LN metastasis,
parametrial invasion and positive resection margin. The
patients with inoperable condition underwent radiation or
chemoradiation therapy. The current study was approved
by the Institutional Review Board of Gangnam Severance
Hospital.
Tissue microarray construction and
immunohistochemistry
Tissue microarrays (TMAs) were constructed using a tissue
arrayer (Pathology Devices, Westminster, MD). Briefly,
slides were reviewed by a pathologist and areas containing
each category were annotated on the H&E slides. Four cy-
lindrical tissue cores of 1.0 mm diameter, consisting of
matched tumor specimen and normal epithelial tissue, were
then taken from the corresponding regions of the paraffin
blocks and transplanted into a recipient paraffin block.
For immunohistochemical staining, all paraffin-embedded
sections were cut at 5 micron thickness, deparaffinized
through xylene and dehydrated with graded ethanols.
Antigen retrieval was performed in heat-activated anti-
gen retrieval pH 6 (Dako, Carpinteria, CA) for HIF-1α
and antigen retrieval pH 9 (Dako) for c-Met, CA9, and
GLUT1, respectively, then specimens were incubated
with 3% H2O2 for 15 min. Non-specific binding blocked
with protein block (Dako) for 20 min at room
temperature. The sections were incubated with anti-
HIF-1α antibodies (Novus Biologicals, Littleton, CO,
Clone ESEE122) at 1:2000 for 30 minutes, anti-GLUT1
antibodies (NeoMarkers, Fremont, CA, Clone SPM498)
at 1:3000 overnight, anti-CA9 antibodies (M75 antibody
Table 1 Characteristics of patients
Variable Frequency %
Age 43.8a
Diagnostic category
Low grade CIN 65 14.1
High grade CIN 144 31.2
CIS 74 16.0
Cervical cancer 179 38.7
FIGO stage
I 123 68.7
II 51 28.5
IV 5 2.8
Tumor differentiationb
Well 2 1.2
Moderate 125 73.1
Poor 44 25.7
Cell type
Squamous cell carcinoma 144 80.4
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and anti-c-Met antibodies (Abcam, Cambridge, MA,
Clone EP1454Y) at 1:500 for 30 minutes, respectively.
Subsequently, sections were incubated with DAKO Env+
secondary antibody for 30 min, visualized with 3,3-
diaminobenzadine for 10 minutes for chromogenic devel-
opment, washed and counterstained with hematoxylin.
Appropriate negative controls were concurrently
performed, and the TMAs included appropriate positive
control tissues.
Digital image analysis
Immunohistochemically stained sections were digitized at
20 × magnification utilizing an Aperio Scanscope CS
(Aperio, Vista, CA). The Aperio Scanscope CS obtains 20 ×
images with a spatial resolution of 0.45 μm/pixels. Images
were reviewed utilizing an online software application,
Digital Image Hub (SlidePath, Dublin, Ireland). Digital
Image Hub enabled users to annotate normal and tumor
regions. Once the areas were annotated, they were sent for
automated image analysis utilizing TissueIA (SlidePath’s
Tissue IA system, version 3.0). Within Tissue IA, an algo-
rithm was developed to quantify cytoplasmic HIF-1α and
membranous c-Met, CA9 and GLUT1. HIF-1α was mainly
stained in the cytoplasm, but partial nucleus staining was
included in the analysis. The output from the algorithm
returns a number of quantitative measurements, namely
the intensity, concentration and percentage of positive
staining present. Quantitative scales of intensity and per-
centage were categorized to 4 and 5 classes, respectively,
after cut-off values were determined. The intensity of stain-
ing was categorized as 0 (no staining), 1+ (weak), 2+ (mod-
erate) and 3+ (strong), and the percentage of staining was
categorized as 0 (≤ 5%), 1+ (6-25%), 2+ (26-50%), 3+ (51-
75%) and 4+ (> 75%). Final IHC score was calculated
from a combination of intensity and percentage score
(Range 0–12) [16].Adenocarcinoma 19 10.6
Adenosquamous 8 4.5
Others 8 4.5
Tumor size
< 4 cm 130 72.6
≥ 4 cm 49 27.4
Lymphovascular invasionc
Negative 93 57.1
Positive 70 42.9
Lymph node metastasisd
Negative 124 75.2
Positive 41 24.8
CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; FIGO, International
Federation of Gynecology and Obstetrics; amean value, bcalculated only 171
cases with available information of growth pattern, ccalculated only 163 cases
with available information of examined lymphovascular invasion, dcalculated
only 165 cases with available information of examined lymph node.Statistical analysis
IHC scores were compared using one-way ANOVA test
and independent t-test. Chi-square test and Spearman's
rank correlation analysis were used to evaluate the associ-
ation between hypoxia related markers. Immunohisto-
chemical cut-off for high expression of tumor markers
was determined through the receiver operating character-
istic (ROC) curve analysis. The sensitivity and specificity
for discriminating death or alive was plotted at each IHC
score, thus generating a ROC curve. The cut-off value was
established to be the point on the ROC curve where the
sum of sensitivity and specificity was maximized [17].
Kaplan-Meier survival analysis was performed to deter-
mine the association of HIF-1α or c-Met expression with
disease-free and overall survival, and the survival curveswere compared between groups using log-rank tests. Uni-
variate and multivariate analyses of hazard ratio for death
were performed using Cox proportional hazards regression.
Statistical analyses were performed using SPSS version 19.0
(SPSS Inc., Chicago, IL). A value of P < 0.05 was considered
statistically significant.
Results
Clinicopathological characteristics of patient cohort
Table 1 summarizes patient’s clinicopathological character-
istics. In 179 patients with cervical cancer, 123 patients of
stage I, 51 of stage II and 5 of stage IV were included. The
ages of the patients ranged from 19 to 83 years (mean,
43.8 years). The tumor sizes ranged from 0.3 to 12 cm
(mean, 2.7 cm). The cervical cancers comprised 144
squamous cell carcinomas (SCC), 19 adenocarcinomas,
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omas, 2 neuroendocrine and 2 mixed cell types). At the
time of last follow-up, recurrence had occurred in 32 of
179 (17.8%) of the cohort. 179 patients were evaluated
for survival analysis and the mean follow-up time of
surviving patients was 55.6 months (range 6 and 60), 17
patients (10%) died during the follow-up period.
Expression of hypoxic and metabolic markers
We examined expression of HIF-1α, c-Met, CA9, and
GLUT1 in cervical neoplasias and cancer specimens by
IHC. Subsequently, we performed analysis of these markers
using automated digital image software. Representative im-
munohistochemical expression of HIF-1α, c-Met, CA9 and
GLUT1 are presented in Figure 1. As shown Figure 1, c-
Met (Figure 1D-1F), CA9 (Figure 1G and 1H) and GLUT1
(Figure 1I) expression was observed in the tumor cell mem-
brane, while HIF-1α expression (Figure 1A-1C) was mainlyFigure 1 Representative immunohistochemical expression for HIF-1α,
no staining in normal cervix (A), weak staining intensity in high grade CIN
c-Met (D-F), CA9 (G, H) and GLUT1 (I) shows cell membranous staining. Re
staining in normal cervix (D), weak membranous staining intensity in squam
carcinoma (F). CA9 expression showing moderate intensity staining in carc
GLUT1 expression showing strong intensity in squamous cell carcinoma (I)observed in the cytoplasm, with some cases also demon-
strating weak nucleus staining. The examples of IHC and
digital image analysis output images are presented in
Figure 2. The green color represents what is classified as
positively stained by the algorithms.
The TMA contains 179 cases of cervical cancer, however
due to the complexity of sectioning, staining, as well as het-
erogeneity of the samples, between 144 and 162 of samples
could be interpreted for the individual markers. One hun-
dred fifty one (84.4%, HIF-1α), 152 (84.9%, c-Met), 144
(80.5%, CA9), and 162 (90.5%, GLUT1) out of 179 cases
were found suitable for IHC evaluation and their detailed
IHC scoring pattern is shown in Table 2. A ROC analysis
was plotted to investigate the optimal cut-off values that
maximized the sum of sensitivity and specificity (Table 3).
HIF-1α and c-Met showed statistically significant AUCs
with 0.677 and 0.650, respectively (P = 0.015 and P = 0.040,
respectively). However, CA9 and GLUT1 did not showc-Met, CA9 and GLUT1. HIF-1α is stained in cytoplasm shown with
(B), and strong staining intensity in squamous cell carcinoma (C).
presentative c-Met expression in cervical samples shown with no
ous cell carcinoma (E) and strong intensity in squamous cell
inoma in situ (CIS) (G) and strong staining in adenocarcinoma (H).
. Scale bar: 50 μm.
Figure 2 Digital image analysis of cytoplasmic and membranous staining. Cytoplasmic HIF-1α staining is shown (A) and automated image
analysis utilizing TissueIA recognizes cytoplasmic HIF-1α staining highlighted in green color (B). CA9 is shown in membranous staining (C) and
automated image analysis determines membranous CA9 staining highlighted in green color (D). The output from the algorithm returns a
number of quantitative measurements for intensity and percentage of positive staining present. Scale bar: 100 μm.
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0.322, respectively). 60 of 151 cancers (39.7%) had high ex-
pression (cut-off value: 8) of HIF-1α, 42 of 152 cancers
(27.6%) had high expression (cut-off value: 8) of c-Met, 45
of 144 cancers (31.3%) had increased expression (cut-off
value: 2) of CA9, 37 of 162 (22.8%) had elevated
expression (cut-off value: 8) of GLUT1. Clinicopathologi-
cal characteristics of HIF-1α, c-Met, CA9 and GLUT1 ex-
pression are summarized in Table 2. HIF-1α, c-Met, CA9
and GLUT1 expression correlated significantly to diagnos-
tic category (Table 2). HIF-1α expression were also corre-
lated significantly to FIGO stage (P < 0.001), tumor cell
type (P = 0.010), LN metastasis (P < 0.001). However,
there was no statistically significant difference in HIF-1α
expression with regard to tumor differentiation, tumor
size and LVSI (Table 2). Statistically significant correlation
was found between c-Met expression and FIGO stage (P =
0.019), LVSI (P = 0.001) and LN metastasis (P = 0.010),
while there was no association between c-Met expression
and tumor differentiation, tumor cell type and tumor size
(Table 2). CA9 immunoreactivity was elevated in non-
squamous cell type (P = 0.040) whereas GLUT1 expres-
sion was significantly increased in squamous cell type(P = 0.001). GLUT1 was highly expressed in negative LN
metastasis compared to positive LN metastasis (P =
0.001).
Association of hypoxic and metabolic markers
To determine the association between expression of
HIF-1α, c-Met, CA9 and GLUT1, HIF-1α score values
were compared with c-Met, CA9 and GLUT1 values
using Chi-square test (data not shown) and Spearman’s
rank correlation analysis (Table 4). Pre-invasive cervical
lesions were evaluated for co-expression between HIF-
1α and its regulated markers. In CIN and CIS speci-
mens, HIF-1α expression showed significant correlation
with GLUT1 (Chi-square test; P = 0.001, Spearman’s rho
= 0.217, P = 0.005) whereas HIF-1α expression was not
correlated with those of CA9 (Chi-square test; P = 0.043,
Spearman’s rho = 0.097, P = 0.195) and c-Met (Chi-
square test; P = 0.136, Spearman’s rho = 0.137, P =
0.062) (data not shown). Of 179 cervical cancer speci-
mens, 148 (82.6%) was available to confirm co-expression
between HIF-1α and c-Met, 131 (73.1%) was available be-
tween HIF-1α and CA9, and 137 (76.5%) was available be-
tween HIF-1α and GLUT1 (Table 4). In CIN and CIS of
Table 2 Association of HIF-1α, c-Met, CA9 and GLUT1 IHC expression with clinicopathological characteristics in
cervical cancer
HIF-1α c-Met CA9 GLUT1
N Mean score
(95% CI)
p value N Mean score
(95% CI)
p value N Mean score
(95% CI)
p value N Mean score
(95% CI)
p value
Diagnostic category < 0.001 < 0.001 < 0.001 < 0.001
Normal a 313 4.4 (4.0-4.7) 346 0.4 (0.3-0.6) 314 0.0 (0.0-0.0) 357 0.9 (0.7-1.1)
Low grade CIN b 54 5.1 (4.3-5.9) 62 0.6 (0.2-1.0) 55 0.4 (0.0-0.8) 40 1.8 (0.9-2.7)
High grade CIN b 104 5.4 (4.9-6.0) 115 0.7 (0.4-0.9) 132 1.9 (1.3-2.5) 121 2.2 (1.8-2.7)
CIS b 56 5.7 (4.9-6.4) 60 1.7 (1.0-2.4) 69 1.3 (0.6-1.9) 73 2.4 (1.7-3.6)
Cervical cancer b 151 5.4 (4.9-6.0) 152 4.7 (4.0-5.3) 144 2.1 (1.5-2.8) 162 4.0 (3.3-4.6)
FIGO stage < 0.001 0.019 0.149 0.243
I 96 4.6 (4.0-5.2) 98 4.2 (3.4-5.0) 95 1.7 (0.9-2.4) 114 4.3 (3.5-5.1)
II 50 6.9 (5.9-7.9) 49 5.2 (3.9-6.4) 45 2.9 (1.6-4.1) 43 3.1 (2.1-4.0)
IV 5 6.0 (2.4-9.5) 5 9.2 (3.7-14.6) 4 4.0 (−5.0-13.0) 5 4.0 (0.4-7.5)
Tumor differentiation 0.350 0.195 0.298 0.169
Well+Moderate 105 5.6 (4.9-6.2) 107 4.4 (3.7-5.2) 105 2.4 (1.6-3.1) 115 4.1 (3.3-4.8)
Poor 40 5.0 (3.9-6.1) 40 5.4 (4.0-6.9) 37 1.5 (0.3-2.6) 41 3.1 (1.8-4.3)
Cell Type 0.010 0.325 0.040 0.001
SCC 119 5.8 (5.2-6.4) 118 4.5 (3.7-5.2) 111 1.6 (1.0-2.3) 130 4.4 (3.7-5.2)
Other 32 4.1 (2.8-5.4) 33 5.3 (3.7-6.9) 33 3.7 (1.8-5.5) 31 1.9 (0.9-2.8)
Tumor size 0.210 0.195 0.851 0.947
< 4cm 104 5.2 (4.6-5.8) 106 4.9 (4.1-5.7) 100 2.2 (1.4-2.9) 119 4.0 (3.2-4.8)
≥ 4cm 47 5.9 (4.9-7.0) 46 4.1 (2.9-5.3) 44 2.0 (0.9-3.1) 43 3.9 (2.8-5.0)
LVSI 0.725 0.001 0.998 0.801
Negative 73 5.0 (4.2-5.7) 74 3.6 (2.7-4.4) 65 2.0 (1.0-3.0) 84 4.0 (3.1-4.9)
Positive 62 5.1 (4.3-6.0) 62 5.9 (4.8-7.0) 63 2.0 (1.0-3.0) 63 4.3 (3.2-5.3)
LN metastasis < 0.001 0.010 0.820 0.001
Negative 100 4.4 (3.9-5.0) 102 4.0 (3.3-4.8) 95 2.0 (1.2-2.8) 113 4.5 (3.7-5.4)
Positive 37 6.7 (5.5-7.9) 36 6.3 (4.8-7.9) 35 2.2 (0.8-3.6) 36 2.6 (1.6-3.6)
Some data of tumor differentiation, LVSI and LN metastasis are not available on retrospective chart review. SCC, squamous cell carcinoma; LVSI, lymphovascular
space invasion; a normal sample was constructed with nonadjacent normal epithelium from tumor in same patient, bIHC staining of each marker was evaluated
with available tumor cores from 209 CIN, 74 CIS and 179 cancer cores.
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c-Met (n = 186, 65.7%), CA9 (n = 181, 64.0%) and GLUT1
(n = 167, 59.0%), respectively. Expression of HIF-1α was
significantly correlated with that of c-Met (P < 0.001 and
Spearman’s rho = 0.351) in cervical cancer specimens
whereas HIF-1α expression showed no association with
CA9 and GLUT1 expression in cervical cancer.Table 3 Optimal cut-off value for high expression was determ
Marker AUROC (95% CI) P value
HIF-1α 0.677 (0.534-0.819) 0.015
c-Met 0.650 (0.499-0.800) 0.040
CA9 0.501 (0.355-0.646) 0.993
GLUT1 0.424 (0.295-0.554) 0.322Survival outcome of hypoxia and metabolic markers
Five year disease-free survival and overall survival were ana-
lyzed through the Kaplan-Meier plots as shown in Figure 3.
In survival analysis of HIF-1α, there were 20 recurrences
and 11 deaths in 60 high expression patients, while 11 re-
currences and 6 deaths in 91 low expression patients were
shown during 5 year follow-up period. Mean 5-year overallined by identifying point to predict death
Prediction of death
Cut-off score Sensitivity (%) Specificity (%)
8 66.7 63.9
8 61.1 76.9
2 23.5 82.7
8 68.7 34.9
Table 4 Correlation of HIF-1α, c-Met, CA9 and GLUT1 IHC expression in cervical cancer
HIF-1α c-Met CA9 GLUT1
n r P n r P n r P n r P
HIF-1α - - - 148 0.351 <0.001 131 0.147 0.094 137 0.034 0.690
c-Met 148 0.351 <0.001 - - - 134 0.135 0.119 139 0.048 0.575
CA9 131 0.147 0.094 134 0.135 0.119 - - - 132 −0.108 0.216
GLUT1 137 0.034 0.690 139 0.048 0.575 132 −0.108 0.216 - - -
r, correlation coefficient; P, p value.
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pressions and high HIF-1α expressions, respectively. High
expression of HIF-1α showed worse disease-free survival
and overall survival rate than those of low expression
group (P = 0.002 and P = 0.047, respectively) (Figure 3A &
E). In survival analysis with c-Met expression, 13 recur-
rences and 10 deaths in 42 c-Met high expressions oc-
curred, while 18 recurrences and 7 deaths were observed
in 110 low expressions. Mean 5-year overall survival time
was 56.5 months in low c-Met expression and 50.8
months in high c-Met expression. High expression of c-
Met showed poorer disease-free and overall survival rate
than low expression group with significant difference (P =
0.035 and P = 0.005, respectively) (Figure 3B & F). How-
ever, CA9 and GLUT1 did not show significant difference
of disease-free survival (Figure 3C and D) and overall sur-
vival (Figure 4G & H) between high and low expression.
When survival of patients with expression of high HIF-1αFigure 3 Kaplan-Meier plots of disease-free survival (A - D) and overa
CA9 (C & G) and GLUT1 (D & H). High HIF-1α expression shows worse di
than low expression (P = 0.047). Patients with high c-Met expression displa
compared with that of patients with low c-Met expression (B & F). P values
of HIF-1α, c-Met, CA9 and GLUT1 are 8, 8, 2 and 8 of IHC score, respectively/high c-Met was compared with that of those with low
HIF-1α/low c-Met, Kaplan-Meier analysis revealed a sig-
nificant difference on both disease-free survival (P = 0.003,
Figure 4A) and overall survival (P = 0.003, Figure 4B).
Univariate and multivariate analysis
Cox proportional hazards analysis was performed to com-
pare the impact of hypoxia and metabolic markers on sur-
vival with those of currently used clinicopathological
prognostic factors (FIGO stage, tumor differentiation,
tumor size, LVSI, LN metastasis) (Table 5). FIGO stage (P =
0.043), LN metastasis (P = 0.008), HIF-1α (P = 0.019) and
c-Met (P = 0.005) showed significant hazard ratio in univar-
iate analysis. We performed multivariate analysis with
separate HIF-1α and c-Met, because both factors are de-
pendent on each other. In multivariate analysis, LN metas-
tasis (P = 0.08 and P = 0.038 for HIF-1α and c-Met,
respectively) and c-Met showed statistical significance inll survival (E – H) for categorized by HIF-1α (A & E), c-Met (B & F),
sease-free survival (A, P = 0.002) and overall survival rate (E, P = 0.047)
yed shorter disease-free (P = 0.035) and overall survival (P = 0.005)
for two-sided log-rank statistics are given for each plot. Cut-off value
.
Low HIF-1α/Low c-Met (n=75)
High HIF-1α/High c-Met (n=27)
Censored
Censored
Low HIF-1α/Low c-Met (n=75)
High HIF-1α/High c-Met (n=27)
Censored
Censored
p= 0.003 p= 0.003
A B
Figure 4 Kaplan-Meier analysis of a combination of HIF-1α and c-Met expression. High HIF-1α/high c-Met revealed a significantly difference
on disease-free survival (A, P = 0.003) and overall survival (B, P = 0.003) compared to low HIF-1α/low c-Met. P values for two-sided log-rank
statistics are given for each plot.
Kim et al. Journal of Translational Medicine 2013, 11:185 Page 8 of 11
http://www.translational-medicine.com/content/11/1/185overall survival (P = 0.041). Meanwhile, HIF-1α did not
show significance under the multivariate analysis.
Discussion
Expression of HIF-1α, c-Met, CA9 and GLUT1 were in-
vestigated in the current study. In those markers, HIF-
1α and c-Met were associated with LN metastasis and
FIGO stage in cervical cancer. HIF-1α and c-Met have
been known as contributing factors for cancer invasion
and LN metastasis in various cancers [18-20]. Activated
HIF-1α under hypoxia reduces tissue integrity through
the loss of E-cadherin, a cell adhesion molecule that acts
as a suppressor of invasion and metastasis [21]. Con-
versely, inhibition of HIF-1α with siRNA induces E-
cadherin expression, which increases cell to cell adhesion
[21]. HIF-1α also facilitates disruption of basement mem-
brane and extracellular matrix which are physical barriers
against tumor cell migration [11]. After HIF-1α disrupts
cell integrity and membrane, c-Met enhances tumor cellTable 5 Cox proportional univariate and multivariate analyse
overall survival in cervical cancer
Univariate analysis Multivariate a
Hazard ratio [95% CI] p value Hazard ratio
FIGO stage (≥IIb) 2.60 [1.02-6.56] 0.043 1.03 [0.3
Tumor grade (poor) 1.39 [0.55-3.51] 0.486 NA
Tumor size (> 4 cm) 2.33 [0.91-5.94] 0.076 NA
LVSI 2.81 [0.99-7.94] 0.050 0.91 [0.1
LN metastasis 4.96 [1.75-13.99] 0.008 4.23 [0.84
HIF-1αb 2.91 [1.09-7.78] 0.019 1.84 [0.5
c-Metc 1.96 [1.22-3.16] 0.005 NA
NA, not applicable; LVSI, lymphovascular space invasion; a Separate multivariate ana
on each other, b Cut-off value of HIF-1α is 8 of IHC score, c Cut-off value of c-Met isto invade surrounding stroma and migrate into the blood
and lymphatic vessels [5,22].
We investigated correlation of HIF-1α expression with
c-Met, GLUT1, or CA9 expression, respectively. Firstly,
HIF-1α expression was associated with c-Met expression
in cervical cancer, while no correlation between HIF-1α
and c-Met was observed in CIN and CIS. Although c-
Met is well known to be regulated by HIF-1α in in vitro
study, its association has not been confirmed with cer-
vical cancer. In our knowledge, this is the first report of
correlation between HIF-1α and c-Met in cervical cancer
tissue. For correlation between HIF-1α and c-Met in
other cancer tissues, only limited number of pancreatic
tissue showed tendency of correlation with c-Met and
HIF-1α expression [23]. Furthermore, correlation be-
tween HIF-1α and c-Met is not reported in pre-invasive
lesions as well. As for pre-invasive cervical lesions, not
only was c-Met found to lack correlation with HIF-1α
but also expressed much lower. Since CIN primarilys of the association between prognostic variables and
nalysis based on HIF-1αa Multivariate analysis based on c-Meta
[95% CI] p value Hazard ratio[95% CI] p value
1-3.40] 0.951 0.96 [0.28-3.25] 0.951
NA
NA
9-4.35] 0.915 0.79 [0.17-3.59] 0.768
-21.34] 0.080 4.83 [1.09-21.42] 0.038
4-6.30] 0.326 NA
3.27 [1.05-10.23] 0.041
lysis for HIF-1α and c-MET was performed because both factors are dependent
8 of IHC score.
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metastasis and invasion, c-Met expression in these cells
is expected to remain low. Regulating factors such as
TGF-β, proteasomal inhibitor, AP1, PI3K and ERK are
involved in the CA9 expression, which are independent
of HIF-1α [24-26].
In this study, c-Met was an independent prognostic factor
on overall survival in cervical cancer. Similar to our study,
c-Met is associated with FIGO stage and LN metastasis,
and c-Met expression influences on the adverse survival
outcome in cervical cancer [20,27,28]. Although the high
expression of HIF-1α revealed worse 5-year overall survival
on Kaplan-Meier plots, HIF-1α did not show significance
on multivariate analysis. In previous studies performed on
patients with cervical cancer, prognostic significance of
HIF-1α was inconsistent, even though the HIF-1α is in-
volved in tumor cell metabolism, invasion and metastasis
[29-31]. Furthermore, even the CA9 and GLUT1, which
play crucial roles in tumor cell metabolism associated with
tumor survival, did not show survival significance in our re-
search. Survival significance of CA9 expression has been
studied in cervical cancer but this remains unclear
[12,32,33]. In the terms of GLUT1, research on its survival
outcome in cervical cancer remains preliminary with very
few reported cases in other cancers [34].
There are numerous potential sources of the conflicting
results of hypoxia markers and prognostic significance in
cervical cancer. Foremost, sampling site is a factor to be
considered. Hypoxia increases as the distance of the sam-
pling site from blood vessel increase, and this contributes
to conflicting results. HIF-1α is stabilized in the cytoplasm
under hypoxic conditions and translocated to the nucleus
as it dimerizes with HIF-1β binding to the hypoxia re-
sponse element. Degree of cytoplasmic and nuclear ex-
pression often varies with different HIF-1α antibodies
used which result in mixed and conflicting outcomes.
Daponate et al. suggested applying a panel of HIF-1α anti-
bodies to overcome controversy [35], however this
approach introduces even more variables, and makes the
application in a clinical setting unappealing. Medical con-
dition of the patient can also affect the expression of hyp-
oxia and metabolic markers. Patients with low level
of hemoglobin and hyperglycemia in diabetes mellitus
exhibited over-expression of HIF-1α and increased GLUT1
expression, respectively [36,37]. Manual scoring is time
consuming, results in qualitative results of limited dynamic
range, and is prone to intra- and inter-pathologist variabil-
ity. The use of image analysis alleviates the issues of vari-
ability, and allows the application of quantitative scoring.
The challenge with automated scoring is ensuring the cor-
rect cells are being quantitated, and many users rely
on manual annotations of regions of interest. Computer-
aided image analysis is limited by the same factors that
manual interpretation are, mainly the quality of theimmunohistochemical staining, and the overall quality of
the tissue being stained [38].
Although HIF-1α expression was significantly higher in
precancerous and cancer tissue than in normal tissue
which was acquired around cancerous tissue, weak or
moderate expression was observed in a large number of
normal tissues. This finding was also observed in other
study including IHC results of esophageal cancer [39].
Hypoxia may influence tissues around the cancerous le-
sions through increased interstitial pressure or metabolic
product to affect oxygen release and consumption [39].
Similar to our result, Birner et al. reported HIF-1α was
highly expressed in high grade CIN and cervical cancer
compared to that in normal cervix but no difference was
observed between high grade CIN and cancer [29]. Consid-
ering such high expression of HIF-1α from high grade
CIN, HIF-1α is thought to be involved in early event of
tumorigenesis. Since human papillomavirus (HPV) infec-
tion is involved in tumorigenesis, much research has been
conducted in finding the association between HPV infec-
tion and HIF-1α. Lu et al. reported double transgenic mice
with HPV 16 and HIF-1α showed highly invasive cervical
cancer compared to that in single transgenic mice only
with HPV 16 expression [40]. HIF-1α expression with
HPV infection facilitates tumor progression from pre-
malignancy to malignancy [40]. Furthermore in other
study, HPV E6 oncoprotein, inactivator of p53 tumor
suppressor gene, was shown to enhance HIF-1α stability
and HIF-1-dependent vascular endothelial growth factor
(VEGF) expression in hypoxia [41]. Considering our find-
ing and together with previous studies, stabilization and
expression of HIF-1α through high-risk HPV infection is
speculated to play an important role in cervical cancer pro-
gression. In addition to HIF-1α, c-Met may co-facilitate
cancer progression with HPV infection as well. In CIN and
anal intraepithelial lesion (AIN), c-Met expression was cor-
related with oncogenic HPV infection but was not corre-
lated with non-oncogenic HPV infection, condyloma
acuminata [42,43]. However, further research is required to
clarify the association between oncogenic HPV and c-Met
expression in cervical cancer progression.
In this study, we evaluated protein expressions of HIF-
1α and its related markers using automated digital image
analysis. Manual interpretation of IHC is highly subjective
and may produce conflicting results among studies. In
such cases, automated digital image analysis for the inter-
pretation of IHC could serve as an alternative method in
presenting reproducible, objective and quantitative mea-
surements. As a result of its ability to predict response to
Trastuzumab, which specifically targets human epidermal
growth factor receptor 2 (HER2), the assessment of HER2
expression has been incorporated in the diagnostic work-
up of breast cancer. Hence, 32.7% of the U.S. laboratories
reported to perform image analysis for quantitation of
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fluorescence in situ hybridization (FISH) is commonly
used to clarify equivocal expression of HER2 by manual
interpretation before administration of Trastuzumab.
However, automated image analysis of HER2 has been
reported to show excellent concordance to FISH results,
while reducing time required for interpretation and being
more user-friendly compared to FISH [15] and therefore,
it may substitute FISH in determination of equivocal case.
Despite of powerful advantages mentioned above, digital
image analysis has not been widely applied to diagnostic
work-up outside breast cancer. As previously applied in
breast cancer research, when used in gynecologic cancer
studies, digital image analysis is expected to improve pro-
tein expression analysis from IHC.
Conclusions
In summary, we have examined the primary players in the
hypoxia signaling pathway, by immunohistochemistry com-
bined with automated digital image analysis, but confirming
their interactions, as well as defining which proteins are as-
sociated with outcome. Among the tested markers, HIF-1α
and c-Met were involved in lymph node metastasis and
tumor stage. Furthermore, our results confirmed the co-
expression of HIF-1α and c-Met in cervical cancer. Both
HIF-1α and c-Met demonstrated poor overall survival in
the univariate analysis, however in the multivariate analysis,
poor overall survival was only associated with c-Met ex-
pression. We demonstrate that c-Met correlates with HIF-
1α and is prognostic factor in survival in cervical cancer.
This data suggest that drugs that target c-Met may have
therapeutic utility in the treatment of invasive cervical
cancer.
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